Castle Biosciences Unveils TissueCypher Data at DDW 2026
FRIENDSWOOD, TEXAS, May 04, 2026 Castle Biosciences has announced the presentation of new clinical data at Digestive Disease Week...
Gastroenterology
Advertisement
Apotex Expands U.S. Portfolio via Cumberland Deal
TORONTO, April 23, 2026 Apotex Inc. and Cumberland Pharmaceuticals Inc. announced a strategic transaction to integrate Cumberland’s U.S. branded...
Spyre to Reveal SKYLINE UC Trial Results on April 13
Waltham, Massachusetts | April 10, 2026 Spyre Therapeutics Inc. has announced that it will report topline results from Part...
TREMFYA® Shows 96-Week Remission in Crohn’s Disease with Fully Subcutaneous Regimen
Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...
FDA Grants RMAT Designation to Avobis Bio’s AVB-114 for Crohn’s Perianal Fistulas
Newark, Del., October 3, 2025 – Avobis Bio LLC, a clinical-stage biotechnology company focused on implantable cell therapies, announced...
Advertisement
